Proverbs 26 vs 5
24 Apr 2018
Re: Takeda I have a lot of PRU. If you want to stay in Pharma then look at Abbott. Merck if you're feeling brave because of their drug for Non Small Cell Lung Cancer.
gamesinvestor
24 Apr 2018
Re: Takeda Yep -- tempted to dump the lot if I see a decent profit, as this is one of my biggest holdings and one I completely misjudged.I'm looking for something with a lot less debt from here on. AZN and GSK won't be on the list.Games
Proverbs 26 vs 5
24 Apr 2018
Re: Takeda I think that you are probably more right than I was.What is your feeling about selling out if the deal goes through? Do you fancy holding the new Takedashire shares?
gamesinvestor
24 Apr 2018
Re: Takeda [link] exact price indicated as yet, but one would assume somewhere north of £47 but less than £50 is a guess with perhaps a further increase in the cash component?Indications that the time can be extended by Shire for further talks, or the whole thing may still fall flat.That risk seems to be in the share price which is still around £40Games
sirgalahad
24 Apr 2018
Takeda Bloomberg TV just announced that a deal is reported to have been agreed but annoyingly I didn't catch a price.
gamesinvestor
24 Apr 2018
Climbing Up 5.22%Something is happening.Games
gamesinvestor
24 Apr 2018
The silence.... is deafening, and such a short time for the bid to be accepted and formally presented.Looking like the big boys aren't interested in Shire.this older article points out some possible reasons why :-[link] from the article :-""""Neither, though, is a “perfect suitor,” he wrote, and they’ve also both “been discussed as having preference elsewhere.” Pfizer, in particular, has long been rumored to be eying Bristol-Myers Squibb and/or AstraZeneca, both key immuno-oncology players that could vault Pfizer’s position in the lucrative field."""Games
gamesinvestor
23 Apr 2018
Re: An extra 50p is not going to do it (... "Not a description of AZN that I would agree with. AZN have repositioned/re-engineered the company as a leader in the developing segment or Immuno-oncology. "Prov, didn't mean to touch a nerve there m8, and I'm not saying AZN could not turn it all around with the proposed new pipeline, but the numbers speak for themselves at least to date anyway.Revenue in 2014 was $26bnRevenue projected in 2018 is expected to be $16bnSo far it's always been jam tomorrow with AZN and the largess on acquisition hasn't gone unnoticed.Even Woody has dumped the stock, well almost all of it anyway, but based on his recent track record, you wouldn't want to put your faith in any of his judgement calls.Games
sound money
21 Apr 2018
Re: An extra 50p is not going to do it (... "In real words that means we have rejected everything so far on the basis that we expect bids from other companies, and as Allergen have now dropped out, we will probably wait over the weekend and if nothing else transpires we'll probably say yes and sell it to the shareholders that the increase in the cash element is the reason."This IMO encapsulates everything. One could argue that the strategic review was a for sale notice . Now that the market knows that the board took this undervalued bid seriously enough to enter negotiations it just confirmed it.Assets this valuable are not available at a knock down price that often. Next week should be interesting.M
Proverbs 26 vs 5
20 Apr 2018
Re: An extra 50p is not going to do it (... "and some won't want to see the opportunity to sell go away like it did at AZN and years later seeing the company struggling with ever falling sales."========== ========== ========== ========== =========Not a description of AZN that I would agree with. AZN have repositioned/re-engineered the company as a leader in the developing segment or Immuno-oncology. I would remind you of the posts on their BB & the FDA approvals.
gamesinvestor
20 Apr 2018
Re: An extra 50p is not going to do it (IMHO... "is considering its position"In real words that means we have rejected everything so far on the basis that we expect bids from other companies, and as Allergen have now dropped out, we will probably wait over the weekend and if nothing else transpires we'll probably say yes and sell it to the shareholders that the increase in the cash element is the reason.We all know that's bowlloxks, but the management want to cash out, so they will say what the shareholders want to hear.It's a mute point of course, whether you think SHP is worth £30, £40, £50 or £60 !!I would have thought patience in growing the business and reducing the debt was the right thing to do, but everyone has a different time horizon and some won't want to see the opportunity to sell go away like it did at AZN and years later seeing the company struggling with ever falling sales.Not saying that would happen to SHP mind but the threat of it may make the management act and recommend and see them all enriched in the short termGames
Proverbs 26 vs 5
20 Apr 2018
An extra 50p is not going to do it (IMHO). Takeda sweetens offer for Shire to £47/shareApr. 20, 2018 9:58 AM ET|About: Shire PLC (SHPG)|By: Douglas W. House, SA News Editor Takeda (OTCPK:TKPYY -4.8%) has bumped its bid for Shire plc (SHPG +1.9%) to £47/share from £46.50.Previously: Shire rejects "undervalued" Takeda bid (April 19)Update: In a statement, Shire acknowledges receiving Takeda's £47/share bid, its fourth, saying the board "is considering its position" and will issue a further announcement in due course.
sound money
20 Apr 2018
Re: today's fall This is just fooling around.Shire has valuable assets full stop. It is very much in play. Others cannot look past this the portfolio is worth more.M
foolish learner
20 Apr 2018
Re: today's fall may not be all over see link[link]
axolotl
20 Apr 2018
today's fall ... presumably it evidences an evaporation of confidence in the likely terms of the takeover and/or the likelihood of a bidding war
